What Are the Key Statistics About Cervical Cancer?
The American Cancer Society's estimates for cervical cancer in the United States for 2017 are:
About 12,820 new cases of invasive cervical cancer will be diagnosed.
About 4,210 women will die from cervical cancer.
Cervical pre-cancers are diagnosed far more often than invasive cervical cancer.
Cervical cancer was once one of the most common causes of cancer death for American women. But over the last 40 years, the cervical cancer death rate has gone down by more than 50%. The main reason for this change was the increased use of the Pap test. This screening procedure can find changes in the cervix before cancer develops. It can also find cervical cancer early − in its most curable stage.
Cervical cancer tends to occur in midlife. Most cases are found in women younger than 50. It rarely develops in women younger than 20. Many older women do not realize that the risk of developing cervical cancer is still present as they age. More than 15% of cases of cervical cancer are found in women over 65. However these cancers rarely occur in women who have been getting regular tests to screen for cervical cancer before they were 65. See the section, " Can cervical cancer be prevented?" and Cervical Cancer Prevention and Early Detection for more information about tests used to screen for cervical cancer.
In the United States, Hispanic women are most likely to get cervical cancer, followed by African-Americans, Asians and Pacific Islanders, and whites. American Indians and Alaskan natives have the lowest risk of cervical cancer in this country.
Welcoming remarks by Dr Osborne E Nyandiva on Symposium: Cervical cancer and its prevention
Co-Presenter Dr Giama. We are happy to present to you this very crucial discussion on Cancer.
Cervical cancer is a type of cancer that develops in a woman's cervix (the entrance to the womb from the vagina).
Cancer of the cervix often has no symptoms in its early stages. If you do have symptoms, the most common is unusual vaginal bleeding, which can occur after sex, in between periods or after the menopause.
Say no to cervical cancer-PUBLIC Awareness-Life Care Centre_Dr.Sharda JainLifecare Centre
Cervical Cancer in INDIA
Say no to cervical cancer
Dr.Sharda Jain
Life Care Centre
PUBLIC Awareness_Dr.Sharda Jain
HPV Infection
HPV Vaccination
Cervical Screening
SEE & TREAT Programme tp Prevent Cervical Cancer
Welcoming remarks by Dr Osborne E Nyandiva on Symposium: Cervical cancer and its prevention
Co-Presenter Dr Giama. We are happy to present to you this very crucial discussion on Cancer.
Cervical cancer is a type of cancer that develops in a woman's cervix (the entrance to the womb from the vagina).
Cancer of the cervix often has no symptoms in its early stages. If you do have symptoms, the most common is unusual vaginal bleeding, which can occur after sex, in between periods or after the menopause.
Say no to cervical cancer-PUBLIC Awareness-Life Care Centre_Dr.Sharda JainLifecare Centre
Cervical Cancer in INDIA
Say no to cervical cancer
Dr.Sharda Jain
Life Care Centre
PUBLIC Awareness_Dr.Sharda Jain
HPV Infection
HPV Vaccination
Cervical Screening
SEE & TREAT Programme tp Prevent Cervical Cancer
Cervical Cancer is common worldwide , ranking 3rd among all malignancies for women.
Second leading cause of cancer death.
Most of these cancers stem from infection with the Human Pappiloma Virus (HPV).
HPV Vaccination, Cerviocal Cancer : Do we need it
for Prevention of cervical cancer &
other HPV related diseasesm,
Presentation Outlines
Cervical cancer disease burden
Prevention with HPV vaccination
Vaccination of sexually active women
Opportunity of Postpartum HPV vaccination
Importance of genital warts prevention
Real world effectiveness data
Safety of HPV vaccine
The Cervical Cancer is the second most common cancers and it can be easily prevented by timely screening & proper education, awareness program for women.
Report Back from SGO 2023: What’s New in Cervical Cancer?bkling
Curious about what’s new in cervical cancer research? Join Dr. Evelyn Cantillo, gynecologic oncologist at Weill Cornell Medicine, as she shares the latest updates from the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer. Dr. Cantillo will also highlight what the research presented at the conference means for you and answer your questions about the new developments.
Cervical Cancer is common worldwide , ranking 3rd among all malignancies for women.
Second leading cause of cancer death.
Most of these cancers stem from infection with the Human Pappiloma Virus (HPV).
HPV Vaccination, Cerviocal Cancer : Do we need it
for Prevention of cervical cancer &
other HPV related diseasesm,
Presentation Outlines
Cervical cancer disease burden
Prevention with HPV vaccination
Vaccination of sexually active women
Opportunity of Postpartum HPV vaccination
Importance of genital warts prevention
Real world effectiveness data
Safety of HPV vaccine
The Cervical Cancer is the second most common cancers and it can be easily prevented by timely screening & proper education, awareness program for women.
Report Back from SGO 2023: What’s New in Cervical Cancer?bkling
Curious about what’s new in cervical cancer research? Join Dr. Evelyn Cantillo, gynecologic oncologist at Weill Cornell Medicine, as she shares the latest updates from the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer. Dr. Cantillo will also highlight what the research presented at the conference means for you and answer your questions about the new developments.
Cancer of the cervix occurs when the cells of the cervix change in a way that leads to abnormal growth and invasion of other tissues or organs of the body.
Human papiloma virus and its association to Cervical Cancer
HPV in Saudi Arabia .
Currently I am working in Arar Central Hospital, in Arar city
In Saudi Arabia.
Please do not hesitate to contact us if you require any further information.
Alsultany@hotmail.com
Cervical cancer by dr alka mukherjee dr apurva mukherjee nagpur m.s.alka mukherjee
Cervical cancer develops in a woman's cervix (the entrance to the uterus from the vagina).
Almost all cervical cancer cases (99%) are linked to infection with high-risk human papillomaviruses (HPV), an extremely common virus transmitted through sexual contact.
Although most infections with HPV resolve spontaneously and cause no symptoms, persistent infection can cause cervical cancer in women.
Cervical cancer is the fourth most common cancer in women. In 2018, an estimated 570 000 women were diagnosed with cervical cancer worldwide and about 311 000 women died from the disease.
Effective primary (HPV vaccination) and secondary prevention approaches (screening for, and treating precancerous lesions) will prevent most cervical cancer cases.
When diagnosed, cervical cancer is one of the most successfully treatable forms of cancer, as long as it is detected early and managed effectively. Cancers diagnosed in late stages can also be controlled with appropriate treatment and palliative care.
With a comprehensive approach to prevent, screen and treat, cervical cancer can be eliminated as a public health problem within a generation.
Anal Cancer - What's the Bottom Line on Vaccination, Screenings, and TreatmentTheSurgeryGroupofLA
Presentation by Yossef Nasseri, M.D.
Yosef Nasseri, M.D., is a founding member of The Surgery Group of Los Angeles, a Los Angeles based physician group providing a comprehensive approach to surgical care through advanced technology, long-term patient follow-up, and direct physician access. Dr. Nasseri is double board-certified in general and colorectal surgery and specializes in cutting-edge robotic and minimally invasive techniques for the treatment of colon and rectal cancers, inflammatory bowel disease, benign anorectal diseases, a variety of hernias, and general surgery.
Nulife module 6 screening for malignancies editedManinder Ahuja
These six modules from 2-7 are on mid life health care of women and were made with intention of training general gynecologist and other speciality into care of mid life women and have Mid Life OPD cards as mainstay of care.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
2. 2
Presentation Overview
• Cervical cancer 101
– Cause: Human Papilloma Virus (HPV)
– “Natural history”
– Treatment
• Preventing cervical cancer
– Avoiding exposure to HPV
– Current screening guidelines
– The new HPV vaccines
3. 3
Cervical Cancer 101
• Abnormal cell growth on cervix (lowest
part of the uterus)
• Caused by HPV infection, especially
during the first years after puberty
• Pre-cancerous changes long before
invasive cancer develops
• Rarely fatal in this country
• A major cause of death worldwide
4. 4
Human Papillomavirus (HPV)
• Long known to cause warts
• Found in many cancers too
• Over 100 types identified
• Most benign, but 15-20 can
cause cancers
• Very common
– 20,000,000 current cases in US
– 6,200,000 new cases annually
– 80% of women have HPV by age 50
– 50% of college students are infected
5. 5
HPV & Cervical Cancer
• HPV recognized as the underlying cause ofHPV recognized as the underlying cause of
cervical cancer since 1996cervical cancer since 1996
– NIH Consensus Conference on Cervical Cancer,
1996
– World Health Organization/European Research
Organization on Genital Infection and Neoplasia,
1996
6. 6
Common HPV Types and their effects
HPV Types Lead to:
Low-Risk
High-Risk
HPV 6, 11,
40,, 42, 43, 44,
54, 61, 70, 72, 81
HPV 16, 18,
31, 33, 35, 39,
45, 51, 52, 56,
58, 59, 68, 73, 82
Benign cervical changes
Genital warts
Precancer cervical changes
Cervical cancer
Anal and other cancers
1. Cox. Baillière’s Clin Obstet Gynaecol. 1995;9:1.
2. Munoz et al. N Engl J Med. 2003;348:518.
7. 7
Human Papillomavirus
Cancer of cervix 100%
Cancer of esophagus .
Cancer of skin .
Cancer of X,Y,Z…. .
Cancer of mouth 3%
Cancer of throat 12%
Cancer of penis 40%
Cancer of vulva, vagina 40%
Cancer of anus 90%
Parkin DM et al. CA Cancer J Clin 2005; 55:74-108.
8. 8
Natural History of HPV Infections
• Sexually transmitted
• Usually no symptoms
• No treatment for HPV infection before symptoms
• Immune system clears most cases; some persist
• HPV present in >99% of cervical cancers
• High risk types (16, 18) associated with cancer
• Low risk types (6, 11) are associated with genital
warts
• All can cause abnormal Pap tests
Human Papillomavirus. ACOG Practice Bulletin No. 61. 2005; 105: 905-18.
9. 9
Co-factors for HPV Infection
•Smoking
•HIV infection
•Other immune system defect
•Pregnancy
•Oral contraceptive use
Ferris et al. Modern Colposcopy. 2004.
10. 10
HPV and Cervical Cancer Rates
by Age
1. Sellors et al. CMAJ. 2000;163:503.
2. Ries et al. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 1973-1997. 2000.
Age (Years)
HPVPrevalence(%)
40-4415-19 20-24 25-29 30-34 35-39 45-49 50-54
0
5
10
15
20
25
30
0
5
10
15
20
25
30
Cancerincidenceper100,000
11. 11
HPV Infections: Summary
• Most people are infected by HPV at some time
• Immune system usually clears HPV, but not always
• Persistent low-risk HPV can lead to genital warts
• Persistent high-risk HPV can lead to pre-cancer
HPV
Long persistence of HPV can
lead to cancer
12. 12
Preventing Cervical Cancer
• Screening for precancerous changes
(and treatment if problems found)
• Vaccination against HPV
13. 13
History of the Conventional
Pap Smear
• Developed by Dr. George N.
Papanicolaou in 1940’s
• Most common cancer
screening test
• Key part of annual
gynecologic examination
• Has greatly reduced cervical
cancer mortality in U.S.
Ferris et al. Modern Colposcopy. 2004: 2-4, 49.
Photo accessed from http://www.cytology-iac.org/Cytopaths/1998/cytoFall98.htm
14. 14
Screening with the
Conventional Pap Smear
• Widely available
• Inexpensive
• But not perfect
– Screening test – not diagnostic
– 7-10% of women need further evaluation
– Low sensitivity – need regular repeats
Cervical Cytology Screening. ACOG Practice Bulletin No. 45. 2003; 102:417-27.
15. 15
New Liquid Pap Tests
• More accurate test
– Thin, uniform layer of cells
– Screening errors reduced by
half
• Screening needed less often
• Can test for HPV with same
specimen if abnormal cells
found
• Expensive
Linder J. et al. Arch Pathol Lab Med. 1998; 122: 139-144.
16. 16
Cervical Cancer Screening Guidelines
• First screen 3 years after first
intercourse or by age 21
• Screen annually with regular Paps or
every 2 years with liquid-based tests
• After three normal tests, can go to
every three years
• Stop at 65-70 years with history of
negative tests
• Still need annual check-ups
Cervical Cytology Screening. ACOG Practice Bulletin No. 45. 2003; 102:417-27.
17. 17
NEW! The HPV Vaccine
Gardasil ® (Merck)
• Protects against types 16, 18, 6, 11
• FDA approved for use in females 9-26 years of age
• Prevents HPV infection; doesn’t treat existing infection
• Virus-like particles (VLP)
• Highly effective
• Safe, few serious adverse side effects
• Requires 3 injections
• Expensive ($360 + administrative fees)
Smith, RA et al. Cancer. 2003;53(1): 27-43.
18. 18
HPV Vaccine
ACOG Recommendations
VACCINATE allVACCINATE all females 9-26 years old,
regardless of sexual activity
• Less potential benefit with increasing age & number of sexual
partners
Special populations – vaccine less effective
• Previous abnormal Pap tests or genital warts
• Immunocompromised
Continue screening with Pap tests!Continue screening with Pap tests!
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
19. 19
NOT CURRENTLY RECOMMENDEDNOT CURRENTLY RECOMMENDED
(Awaiting more evidence)(Awaiting more evidence)
Continue screening with Pap tests!Continue screening with Pap tests!
• Women over age 26
• Pregnant women
– If vaccine started before pregnancy, give
remaining dose(s) post-partum
• Breastfeeding women
• Men
HPV Vaccine
ACOG Recommendations
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
20. Medical Treatment with Herbs
20
• Habbatussauda (Nigella sativa
Linn/Black Cumin)
Black cumin can cure cancer. Black cumin Medicinal Plants contain
fatty acids that can prevent the growth of cancer cells. And not only
that's just black cumin also has the ability to be able to stimulate the
bone marrow production. Intereron production and can improve the
immune system in the body's cells. and by consuming black cumin then
normal body cells that still can be properly maintained and have the
ability to fight and to kill cancer cells in the body.
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
21. Medical Treatment with Herbs
21
• Selaginella doederleinii Hieron
Sri Handayani research results SFarm Apt MSi of Chemistry LIPI
Research Center, proving Selaginella doederleinii Hieron
extract can kill breast cancer cells. "The study was the first step in order to
scribble recognized as standardized herbal as required by the Food and
Drug Monitoring Agency (BPOM)," said the alumnus of Gadjah Mada
University.
Furthermore Handayani test the inhibitory concentration (IC) 50 to 96
Selaginellaextract cell cultures of MCF - 7 breast cancer cells resistant
to chemotherapy. IC50 value indicates the level of concentration of the
extract to menghazmbat or shut down 50% of the test cell. The results
showed the IC50 value reaches 61 ug / ml. That is, with a concentration
of 61 ug / ml, chicken claw extract is able to inhibit or shut down 50% of
cancer cells.
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
22. Medical Treatment with Herbs
22
• Hedyotis corymbosa
Hedyotis corymbosa contains hentriakontane, stikmasterol, ursolic acid,
sitosterol, D-glucoside, p- coun Maric acid, flavonoids glycossides and
oleic acid. Members familli Rubiaceae This is a sweet, slightly bitter,
soft neutral and rather cold. Boondoggle to remove heat and toxic anti-
inflammatory, diuretic, heals ulcers and activate blood circulation.
Lymphosarcoma cancer, gastric cancer, cervix, breast cancer, rectal
cancer, nasopharyngeal cancer: About 50 gr crops washed, then boiled
with 14 cups water to boil, culture up to 2 cups of water, then remove
from heat. When cool, strain the decoction and drink 2 times a day,
each 1 cup.
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
23. Medical Treatment with Herbs
23
• Andrographis paniculata Ness
CHEMICAL CONTENT: Leaves and branched containing laktone
consisting of deoksiandrografolid, andrographolide (bitter
substances), neoandrografolid, 14-deoxy-11-12-
didehidroandrografolid, and homoandrografolid. Also there are
flavonoids, alkane, ketone, aldehyde, minerals (potassium,
calcium, sodium), acid grit, and resin. Flavotioid isolated most of
the roots, namely polimetoksiflavon, andrografin, pan.ikulin,
mono-0- metilwithin, and apigenin-7,4- dimetileter. The active
substance andrographolide proved efficacious as
hepatoprotektbr (protects liver cells from toxic substances).
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
24. Medical Treatment with Herbs
24
• Garlic / Aglio
Garlic Herbal Anti-Cancer
Wowwww, at least that's the reaction been discovered by researchers when
researching properties of garlic for the most dangerous disease of
cancer. Garlic is worth mentioning as herbal / plant anti-cancer, contain
allyl sulfides contained in garlic as a herbal anti-cancer causes.
One of the clear evidence that the researchers discovered is the content of
PhIP, one form of heterocyclic amines (HCAs), which are substances
that can trigger breast cancer for women. From various studies
conducted diallyl sulphide substances contained in garlic inhibits the
growth and transformation into a carcinogen PhIP that can eventually
lead to breast cancer.
But you should remember that garlic has anti-cancer agent that is effective
to prevent the growth of cells of various types of cancer that are harmful
to you.
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
25. 25
HPV Vaccine
Important Considerations
Continue screening with Pap tests!Continue screening with Pap tests!
• Vaccine is most effective before first sexual
intercourse – less effective in sexually active
women
• HPV testing before vaccine not
recommended
• Vaccine is not a treatment for current HPV
infection, genital warts, or pre-cancer
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
26. 26
HPV Vaccine FAQ
• Vaccine will not cause HPV
– Virus-like particle vaccine (not live virus)
• HPV vaccines appear to be very safe
– Few major adverse events, but limited data
• Most side effects are minor
– Injection site reaction
• Potentially effective in preventing cervical cancer
(and other HPV-related cancers)
– BUT not all cancer-causing HPV types are covered by the
vaccine
Continue screening with Pap tests!Continue screening with Pap tests!
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
27. 27
HERBS
ANT NESTS HERBAL CAPSULE (DRUG DISEASEANT NESTS HERBAL CAPSULE (DRUG DISEASE
CANCER / TUMOR) HIUCANCER / TUMOR) HIU
BPOM POM TR 133 373 081
• Treating cancer and tumors
• Treating Coronary Heart and various cardiovascular disorders
• Treating Stroke heavy and light,
• Treat Lupus, Ambien (Hemorrhoids) • Eliminate the lumps in the breast
• Troubleshooting kidney and prostate, tuberculosis and lung problems
• Ambien (Hemorrhoids) new and old
• Blood circulation
• Overcoming stiff and sore muscles • Increase vitality • Improve and increase stamina
Composition:
Myrmecodia pendans 100%
ATTENTION!
Not recommended for pregnant women, nursing mothers and children under 2 years
Price Rp. 99.000, - (Excluding Shipping)
Please contoact (For All Herbs Products)
SMS / WA / skype + 62856-4O-53-5O-8I
email / fb: gudangmuslimindo@gmail.com
PIN: D7C0456A
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
28. 28
HERBS
KELADIKAPS simplisia Typhonium flagelliforme Rhizoma CAPSULEKELADIKAPS simplisia Typhonium flagelliforme Rhizoma CAPSULE
EXTRACT (Herbal Cancer Tumor)EXTRACT (Herbal Cancer Tumor)
Contents: 60 capsules
Permits: POM TR 103 310 201
Some recent studies mentioned plants simplisia Typhonium flagelliforme Rhizoma proved to have
efficacy to destroy cancer cells, but it would be difficult to find this plant sanagat let alone cultivate it to
be consumed as a drug. Now comes, the solution easily consume taro mice with the rodent tuber
extract KELADIKAPS.
composition:
simplicia Typhonium flagelliforme Rhizoma (tuber taro rat)
Keladikaps efficacy of rodent tuber extract:
In tradisisonal used for cancer patients
Drinking rules:
Taken 2 times daily morning and afternoon 2 capsules
WARNING !!!!
• Pregnant women are prohibited from taking this medicine.
• After the operation should not immediately drink taro rat, wait 2 weeks.
• The first two days after drinking may be nausea, diarrhea sedikti, black dirt, and lethargic.
Sometimes vomiting or nausea after drinking simplisia Typhonium flagelliforme Rhizoma , put an end
to or subtract.
ATTENTION!
Not recommended for pregnant women, nursing mothers and children under 2 years
Price Rp. 59.900, - (Excluding Shipping fee)
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
29. 29
HERBS
CYSTOGA CV Toga NusantaraCYSTOGA CV Toga Nusantara
(Herbal Overcoming cancer and(Herbal Overcoming cancer and
cysts)cysts)
PRODUCT BRIEF:
Contents: 50 Capsules @ 500 mg
Permit BPOM: POM TR 113 328 011
Composition:
• Curcumae zadoaria rhizome extract 175 mg
• herb Andrographis extract 125 mg
• Gynura Folium 100 mg
• Curcumae Xanthoria rhyzoma extract 100 mg
Drink suggestion:
-Adults 3 x 2 capsules a day, taken 1 hour
before meals
Price Rp. 59.950,-
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
30. 30
HERBS
HERBAL HERBAMED "BENCALANG" ANTI CANCER /HERBAL HERBAMED "BENCALANG" ANTI CANCER /
TUMORTUMOR
1 Pack Contains 2 Bottle @ 50 capsules @ 250mg
Permit BPOM: POM TR. 103 310 911
Ben Ca Lang, with 2 Bottles, Efficacy of more than 2 x. EXTRAORDINARY!
In 1 Package Ben Ca Lang, there are two bottles of herbal capsules Ben Ca Lang Herbamed
1. Ben Ca Lang Cancer
Composition:
Each capsule contains extracts:
1.) Thyponium Flagelliforme 50 mg 2.) CentellaAsiatica 40 mg 3.) Androgs 35 mg 4.) Merremia
Raphis Panic 40 mg 5.) LoranthuMammosa 30 mg 6.) Curcumae zedoaria 30 mg 7.) Gynura
Precumbents 25 mg
benefit
1. Helps Turn off the cancer cells by splitting the nucleus of cancer cells
2. Inhibit the growth and spread of cancer cells
3. To revitalize the entire network and spread of cancer cells
4. Improving the body's cells
5. Increase endurance and stamina
MUST BE CONSIDERED!
Ben Ca Lang cancer must be taken together with Ben Ca Lang Angion
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
31. 31
HERBS
HERBAL HERBAMED "BENCALANG" ANTI CANCER /HERBAL HERBAMED "BENCALANG" ANTI CANCER /
TUMORTUMOR
11 Pack Contains 2 Bottle @ 50 capsules @ 250mg
Permit BPOM: POM TR. 103 310 911
In 1 Package Ben Ca Lang, there are two bottles of herbal capsules Ben Ca Lang
Herbamed
MUST BE CONSIDERED!
Ben Ca Lang cancer must be taken together with Ben Ca Lang Angion
Ben Ca Lang Angion
Composition
Each capsule contains extracts:
1.) Arecha catechu 50 mg 2.) Phyllanthus urinary 38 mg 3.) Catharanthus roseus 50
mg 4.) Ganoderma Lucidum 38 mg 5.) Eleuthorine Americana 74 mg
property
1. Stopping the formation of new blood vessels, without blood cells, tumor cells /
cancer will die
2. Destroying cancer cells
3. Preventing the cancer cell division
4. Inhibits cancer cell growth
5. Strengthening the immune system
How to use
3 x 3 capsules / day. 30 minutes before meals (Price Rp. 175.000,-)
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
32. 32
HERBS
ALBIMOR Al Biruni (Herbs for Cancer / Tumor)ALBIMOR Al Biruni (Herbs for Cancer / Tumor)
Contents: 50 Capsules
Permit BPOM: POM TR. 103 309 941
COMPOSITION:
• Nigella sativa, Selaginella doederleinii, Hedyotis corymbosa, Andrographis paniculata, etc.
Recommendation:
Reduce consumption of bean sprouts, longan, jackfruit, MSG, durian, tape, pineapple, soft drinks,
ice, chicory, kale, chili, salt, salted fish, and avoid alcohol.
Not for pregnant women and children
DESCRIPTION:
Benefits:
• Killing cancer cells
• Inhibit the growth of cancer cells
• Increase endurance
• Reduces pain from cancer
• Strengthening the tissue cells around the cancer
• Reducing the adverse effects of chemotherapy
Rp. 69.100,-
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
34. 34
References
Advisory Committee on Immunization Practices. ACIP provisional recommendations for the use of quadrivalent HPV vaccine.
August 14, 2006. Accessed from http://www.cdc.gov/nip/recs/provisional_recs/hpv.pdf.
American Cancer Society. Cancer facts and figures 2003. Atlanta (GA): ACS 2003. Available at
http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf.
Apgar BS, et al. “The 2001 Bethesda System Terminology.” Am Fam Physician. 2003;68:1992–1998.
Cannistra SA, Niloff JM. “Cancer of the Uterine Cervix.” N Engl J Med. 1996;334:1030–1038.
Cates W Jr, and the American Social Health Association Panel. “Estimates of the incidence and prevalence of sexually
transmitted diseases in the United States.” Sex Transm Dis. 1999;26(suppl):S2–S7.
Centers for Disease Control and Prevention. Rockville, Md: CDC National Prevention Information Network; 2004.
Cervical Cytology Screening. ACOG Practice Bulletin No. 45. American College of Obstetricians and Gynecologists. Obstet
Gynecol 2003; 102:417-27.
Cox. Baillière’s Clin Obstet Gynaecol. 1995;9:1.
Ferris et al. Modern Colposcopy: Textbook and Atlas. 2nd ed. Dubuque, Iowa: Kendall/Hunt; 2004: 2-4, 49, 78-82.
Howley PM. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 4th ed. Philadelphia, Pa: Lippincott-Raven;
2001:2197–2229.
Human Papillomavirus. ACOG Practice Bulletin No. 61. American College of Obstetricians and Gynecologists. Obstet
Gynecol 2005; 105: 905-18.
Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. American College of Obstetricians and
Gynecologists. Obstet Gynecol 2006; 108: 699-705.
Hutchinson ML. et al. “Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep
Processor.” Am J Clin Pathol. 1994; 101:215-219.
Jansen KU, Shaw AR. ”Human Papillomavirus Vaccines and prevention of cervical cancer.” Annu Rev Med. 2004;55:319–
331.
Kodner CM, Nasraty S. “Management of genital warts.” Am Fam Physician. 2004;70:2335–2342.
Lacey CJN. “Therapy for genital human papillomavirus-related disease.” J Clin Virol. 2005;32(suppl):S82–S90.
Linder J. et al. “ThinPrep Papanicolaou testing to reduce false-negative cervical cytology.”Arch Pathol Lab Med. 1998; 122:
139-144.
Management of Abnormal Cervical Cytology and Histology. ACOG Practice Bulletin No. 66. American College of
Obstetricians and Gynecologists. Obstet Gynecol 2005; 106: 645-64.
Maw RD, Reitano M, Roy M. “An international survey of patients with genital warts: perceptions regarding treatment and
impact on lifestyle.” Int J STD AIDS. 1998;9:571–578.
35. 35
References (Cont.)
McCrory DC, Matchar DB, Bastian L, et al. Evaluation of Cervical Cytology. Evidence Report/Technology Assessment
No. 5. AHCPR Publication No. 99-E010. Rockville, MD: Agency for Health Care Policy and Research. February
1999.
Moscicki, A.B. et al. “Updating the natural history of HPV and anogenital cancer.” Vaccine. 2006; 24S3; 42-51.
Munoz et al. “Epidemiologic classification of human papillomavirus types associated with cervical cancer.” N Engl J
Med. 2003;348:518.
Ostor, AG. “Natural history of cervical intraepithelial neoplasia: a critical review.” Int J Gynecol Pathol 1993; 12(2): 186-
92.
Parkin DM, Bray F, Ferlay J, Pisani P. “Global cancer statistics 2002.” CA Cancer J Clin 2005; 55:74-108.
Ries et al. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 1973-1997. 2000.
Saslow D et al. “American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer.” CA
Cancer J Clin. 2002;52:342-362.
Schiffman M, Castle PE. “Human papillomavirus: Epidemiology and public health.” Arch Pathol Lab Med.
2003;127:930–934.
Schiffman M ASCCP 2002 Biennial Orlando, Fl.
Sellors et al. “Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada.” CMAJ.
2000;163:503-8.
Smith, RA et al. “American Cancer Society Guidelines for the Early Detection of Cancer, 2003.” Cancer. 2003;53(1):
27-43.
Solomon D, Davey D, Kurman R, et al, for the Forum Group Members and the Bethesda 2001 Workshop. JAMA.
2002;287:2114–2119.
Soper DE. In: Berek JS, ed. Novak’s Gynecology. 13th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:453–
470.
Spitzer M, Johnson C. Philadelphia, Pa: WB Saunders Co; 2002:41–72.
Wiley DJ, Douglas J, Beutner K, et al “External genital warts: diagnosis, treatment and prevention.” Clin Infect Dis.
2002;35(suppl 2):S210–S224.
Winer RL et al. “Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university
students.” Am J Epidemiol. 2003; 157:218-226.
Wright, T.C. et al. “2001 Consensus Guidelines for the Management of Women with Cervical Cytological
Abnormalities.” JAMA. 2002; 287: 2120-2129.
USPSTF. 2003. Available at http://www.ahrq.gov/clinic/uspstf/uspscerv.htm.
36. 36
Questions?
Program sponsored by
Middle Earth
Slide set developed with help from
Dr. Kim Noyes
Preventive Medicine Resident, School of Public Health
Information provided by the New York State Department of Health,
Cancer Services Program
Please take a few momentsPlease take a few moments
to complete the evaluation!to complete the evaluation!
Editor's Notes
Key Point
There are many different types of HPV; of the 15–20 oncogenic types, HPV 16 and HPV 18 account for the majority of cervical cancers.
The disease burden is large. HPV is very prevalent, especially among young sexually active teens and adults.
Background
Papillomaviruses such as HPV are nonenveloped, double-stranded DNA viruses. More than 100 HPV types have been detected, with >80 types sequenced and classified. Approximately 30–40 types of HPV are anogenital, of which 15–20 types are oncogenic. HPV Types 16 and 18 are oncogenic and account for about two thirds of all cervical cancers. HPV Types 6 and 11 are nononcogenic and are associated with external anogenital warts and RRP.
References
1. Schiffman M, Castle PE. Human papillomavirus: Epidemiology and public health. Arch Pathol Lab Med. 2003;127:930–934.
2. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: Diagnosis, treatment, and prevention. Clin Infect Dis. 2002;35(suppl 2):S210–S224.
The causal role of human papillomavirus in all cancers of the cervix has been firmly established biologically and epidemiologically.
Reference: Munoz, N. et al. “HPV in the etiology of human cancer.” Vaccine 24S3 2006;24S3: 1-10.
Low-risk HPV types, such as types 6 and 11, most commonly cause benign low-grade cervical changes and genital warts.
Types 16 and 18 and other “high-risk” HPV types are the most common cause of low-grade cervical cell abnormalities, and almost exclusively cause high-grade cervical cell abnormalities that are precursors to invasive cervical cancer and other lower genital tract malignancies including vulvar, vaginal, penile and anal cancer.
The large IARC study of cervical cancers around the world demonstrated that over 90% of all of cervical cancers were associated with high-risk types of HPV
Irrespective of geographical area
43% to 65% of the cancers were associated with HPV 16
8% to 31% were associated with HPV 18.
Taken together, HPV 16 and 18 accounted for approximately two-thirds of all invasive cancers from all geographic areas.
References:
1. Cox. Baillière’s Clin Obstet Gynaecol. 1995;9:1.2. Munoz et al. N Engl J Med. 2003;348:518.
HPV is implicated as the cause of cervical cancer and many other ano-genital cancers.
Reference: Parkin DM, Bray F, Ferlay J, Pisani P. “Global cancer statistics 2002.” CA Cancer J Clin 2005; 55:74-108.
Genital HPV is transmitted sexually. Transmission occurs through contact with infected genital skin, mucous membranes, or body fluids from a partner with either overt or subclinical HPV infection. Other modes include oro-genital, manual-genital, and nonpenetrative genital-genital contact.
Covering infected areas with a latex condom provides theoretical protection from infection. Areas not covered by condom can transmit HPV infection.
Infrequently transmitted in the neonatal period, although published studies are conflicting.
Most HPV infections are transient and are cleared by the immune system
70-90% will clear within 1-2 years
Persistent HPV viral infections may lead to cancer and its precursors
No treatment for HPV infection but cervical changes and warts CAN be treated
Reference: Human Papillomavirus. ACOG Practice Bulletin No. 61. American College of Obstetricians and Gynecologists. Obstet Gynecol 2005; 105: 905-18.
Co-factors to HPV in cervical carcinogenesis may act in at least 3 ways:
By influencing the acquisition of HPV infection (OCPs, multiparity)
By increasing the risk of HPV persistence (HIV, immunosuppresion)
By increasing the risk of progression from HPV infection to CIN 2,3 and cancer (smoking, multiparity)
Cigarette smoking is a significant and independent risk factor for the development of CIN3 and SCC of cervix, increasing RR 2-5 fold. Risk increases with increased intensity and duration of smoking. Mechanism is likely that tobacco containing carcinogens promote neoplastic progression in HPV infected cells.
HIV and other immunosupression cause an inability to clear HPV, increasing susceptibility to HPV and oncogenicity.
Multiparity has been found to be associated with both cervical cancer and CIN3 with risk rising with increased number of pregnancies. Effect is independent of sexual behavior and socioeconomic variables. Pregnancy-induced alterations in nutritional status, the effects of hormones on the cervix or on HPV expression, increased susceptibility to potential mutagens or effect of trauma at delivery are proposed mechanisms.
OCP use conveys a measurable increase in risk for SCC. The strongest evidence comes from an IARC multicenter case-control study demonstrating only a moderate association with cancer risk. Mechanism appears to be the physiologic effects such as eversion of the columnar epithelium, thus activating HPV-vulnerable immature squamous metaplasia.
Reference: Ferris et al. Modern Colposcopy. 2004: 2-4, 78-82..
This graph shows HPV prevalence and cervical cancer incidence as a function of a woman’s age.
Key observations
In younger women, there is a high prevalence of HPV infection but that cervical cancer is very rare.
As women age, the prevalence of HPV declines and the incidence of cancer increases.
Women over 30 years of age have a greater risk for developing high-grade lesions and cancer.
Women with persistent high-risk HPV infections are the population most at-risk for having or developing cervical cancer.
References:
1. Sellors et al. CMAJ. 2000;163:503.
2. Ries et al. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 1973-1997. 2000.
**Note: Data from the CMAJ study was collected from women aged 15-49, whereas the SEER data reported cancer incidence in all age-segments of the population.
In summary
Most will get HPV at some time during their lifetime
Most, even with high-risk HPV, will clear or permanently suppress the virus.
However, some do not.
It is persistence of high-risk HPV that can lead to true pre-cancer
Long persistence of high-risk HPV and HPV-induced CIN3 are necessary for the accumulation of random mutations that lead to cancer.
Primary cervical cancer screening essentially began with the introduction of the Pap Smear.
Introduced in the 1940’s, by Dr. George N. Papanicolaou, the pap smear eventually became the standard screening test for cervical cancer and pre-malignant lesions.
The Pap test is based on a relatively simple principle. Cells from squamous epithelium exfoliate over time. Thus, the cells removed for cytologic examination represent epithelial cells, normal or abnormal, found at the surface.
Widespread use of the pap smear has decreased cervical cancer deaths by 70%.
Reference: Ferris et al. Modern Colposcopy. 2004: 2-4, 49.
Cervical cytology screening is, in many respects, the ideal screening test.
Cervical cancer has a defined premalignant phase of many years, which allows repeated tests to significantly reduce the impact of individual false-negative test results.
Cervical cytology is inexpensive and is readily accepted among American women.
However, cervical cytology, is not a diagnostic test. The sensitivity of the pap smear is low (ranges from 47-85%) and the specificity is high (95-98%).
Reference: Cervical Cytology Screening. ACOG Practice Bulletin No. 45. 2003; 102:417-27.
In 1996, the FDA approved the first of two currently available liquid-based thin-layer cytology preparations for cervical screening.
Liquid-based thin-layer cervical cytology was introduced to help reduce the potential sampling errors. The Thin-Prep method appears to have increased sensitivity for detecting cancer precursor lesions over the conventional method, but the degree to which sensitivity is increased is unknown. The reported increase in sensitivity may make this method especially useful in women who are screened infrequently (fewer false negatives).
The difference in specificity between the liquid-based and conventional tests has not been determined. Although an increase in sensitivity will permit earlier detection of cancer precursor lesions, any decrease in specificity can result in increased cost and morbidity from false-positive diagnoses.
Both the conventional test and the liquid-based thin-layer test can be effective in population screening.
Providers selecting a cervical cytology method should consider the screening history of their patient, the cost of the test, and the possible effects of false-negative or false-positive results.
Reference: ACOG Practice Bulletin. Cervical Cytology Screening. 2003; 45:1-11.
The next several slides will review the newest guidelines for cervical cancer screening from the American Cancer Society, the United States Preventive Services Task Force and the American College of Obstetricians and Gynecologists.
These guidelines specifically state how often screening should be done, when to initiate screening and when screening can be discontinued.
Reference: Cervical Cytology Screening. ACOG Practice Bulletin No. 45. 2003; 102:417-27.
Key points:
The only currently available, FDA approved HPV vaccine is Gardasil, manufactured by Merck.
It is a quadrivalent vaccine, effective against 4 HPV types: 6, 11, 16, and 18.
Highly efficacious
Only approved for use in females 9-26 years old.
$120/dose plus cost of administering/physician charge, etc.
Reference: Cancer 2003;53(1): 27-43.
Important points:
Vaccination recommended for all females 9-26 years old.
Vaccine is most effective if administered before sexual activity
ACOG supports vaccination at 13-15 years of age during first visit to GYN
The vaccine can be given to women with previous CIN, abnormal cytology or genital warts, but it is not intended to treat these patients. Patients with these conditions should undergo the appropriate evaluation and treatment.
Women with suppressed immune systems can be vaccinated, although protection may be less than that of women with normal immune function.
Pap screening recommendations remain the same. The vaccine is a preventive tool and is not a substitute for cancer screening.
Reference: Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
Important Points:
Vaccination of women over age 26 and of males is not currently recommended.
Pregnant women should not be vaccinated. The FDA classifies it as pregnancy category B. Although its use in pregnancy is not recommended, no teratogenic effects have been reported in animal studies. In clinical studies, the proportion of pregnancies with an adverse outcome were comparable in women who received the quadrivalent HPV vaccine and in women who received a placebo. If a woman discovers she is pregnant during the vaccine schedule, she should delay finishing the series until after she gives birth. The manufacturer’s pregnancy registry should be contacted if pregnancy is detected during the vaccination schedule.
It is unclear whether vaccine can be provided to women who are breastfeeding because inactivated vaccines do not affect the safety of breastfeeding for mothers or infants. It is not known whether vaccine antigens or antibodies found in the quadrivalent vaccine are excreted in human milk. ACOG and ACIP state that lactating women can receive the vaccine.
Reference: Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
The Advisory Council on Immunization Practices has recommended the initial vaccination target of females aged 11 or 12. This is part of the “adolescent platform” that supports a routine well-child check at age 11-12 that would include discussion of HPV vaccine and other recommended immunizations (DTaP and Meningitis).
In summary
The earlier the vaccine is given, the better
Continue cervical cytology screening
Vaccine is prophylactic, not treatment
Reference: Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
Health care providers are encouraged to discuss with their patients the benefits and limitations of the quadrivalent HPV vaccine and the need for continued routine cervical cytology screening.
Reference: Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
Health care providers are encouraged to discuss with their patients the benefits and limitations of the quadrivalent HPV vaccine and the need for continued routine cervical cytology screening.
Reference: Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
Health care providers are encouraged to discuss with their patients the benefits and limitations of the quadrivalent HPV vaccine and the need for continued routine cervical cytology screening.
Reference: Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
Health care providers are encouraged to discuss with their patients the benefits and limitations of the quadrivalent HPV vaccine and the need for continued routine cervical cytology screening.
Reference: Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
Health care providers are encouraged to discuss with their patients the benefits and limitations of the quadrivalent HPV vaccine and the need for continued routine cervical cytology screening.
Reference: Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
Health care providers are encouraged to discuss with their patients the benefits and limitations of the quadrivalent HPV vaccine and the need for continued routine cervical cytology screening.
Reference: Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
Health care providers are encouraged to discuss with their patients the benefits and limitations of the quadrivalent HPV vaccine and the need for continued routine cervical cytology screening.
Reference: Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.
Health care providers are encouraged to discuss with their patients the benefits and limitations of the quadrivalent HPV vaccine and the need for continued routine cervical cytology screening.
Reference: Human Papillomavirus Vaccination. ACOG Committee Opinion No. 344. 2006; 108: 699-705.